MIAMI, FL, USA I September 9, 2015 I OPKO Health, Inc. (NYSE: OPK) today announced a global license agreement with The Scripps Research Institute (TSRI) for the development and commercialization of novel lipoprotein signal peptidase (“Lsp”) inhibitors developed and discovered using a proprietary high throughput screening technology funded and exclusively licensed by OPKO from TSRI.

“This technology is one of the best opportunities we have for the development of specific inhibitors of Lsp, which represents a remarkable target for the development of broad and novel antimicrobial agents, as it is highly conserved throughout the bacterial and mycoplasma kingdoms and no human homologues exist,” said TSRI Professor Dennis Wolan, Ph.D., who led the research on this screening platform.

OPKO has agreed to fund additional work in Dr. Wolan’s laboratory at TSRI and to move as rapidly as possible into clinical trials.

“We are pleased to continue our collaboration with Dr. Wolan and The Scripps Research Institute to develop the next generation of highly effective antibiotics,” said Phillip Frost, M.D., Chairman and Chief Executive Officer. “Our plan is to continue to build on two promising leads already identified and others using the novel screening technology developed at Scripps.”

There is a tremendous unmet medical need for new, potent antibiotics.

About OPKO Health

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. For more information, visit

About The Scripps Research Institute

The Scripps Research Institute (TSRI) is one of the world’s largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs about 2,700 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including two Nobel laureates—work toward their next discoveries. The institute’s graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see